Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bronchopulmonary PK of Anidulafungin and Voriconazole in Healthy Subjects
NCT00940017Phase 4Completed
- Sponsor
- Pfizer
- Start
- Sep 2008
- Primary completion
- Oct 2008
- Modality
- Cyclic Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of anidulafungin and voriconazole in aspergillosis and candidemia, sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 24 hours, Time to Reach Maximum Plasma Concentration at 24 hours and 1 more. Started Sep 2008; status: completed.
02
Drugs
anidulafunginvoriconazole
03
Conditions
aspergillosiscandidemia
Beyond the preview
Go deeper on NCT00940017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00940017.